G2
Peptide vaccine for treatment of IDH1 R132H mutant-positive cancers (P-987)
Prof. Michael Platten, German Cancer Research Center; Prof. Wolfgang Wick, University Clinic Heidelberg; Dr Theresa Schuhmacher, University Clinic Heidelberg
DKFZ
Challenge
Mutations in the human isocitrate dehydrogenase type 1 (IDH1) gene affecting position 132 (R132H) were originally detected in glioma. Since these types of brain tumors, accompanied by IDH1 R132H mutation, are usually aggressive and associated with a poor prognosis, effective therapies and proper diagnostic tools are urgently needed in clinical practice. State of the art diagnosis of IDH1 R132H mutation in cancer requires tissue samples, which are obtainable only via cumbersome and potentially dangerous biopsy.
Technology
The peptide referring to the present invention can be used in several ways for detection of cancers accompanied by IDH1 R132H mutation simply by using blood samples.- Binding of the peptide to antibodies against IDH1 R132H present in blood serum of cancer patients
- Stimulation of T-cells obtained from patients suffering from tumors accompanied by IDH1 R132H mutationIn addition the peptide can initiate an immune response against tumor cells accompanied by IDH1 R132H mutation in vivo.
Commercial Opportunity
Diagnosis of IDH1 R132H mutation in tumor cells without the need for biopsy. In addition the peptide can be used for therapeutic vaccination and subsequent immune monitoring.
Development Status
Diagnostic method, readouts: a) antibody binding to peptide; b) T-cell stimulation by peptide. Clinical Phase I Trial IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas (NOA-16) ongoing as NCT02454634.
Patent Situation
Priority patent application “Means and methods for treating or diagnosing IDH1 R132H mutant-positive cancers” EP 12150298.3; international PCT published as WO 2013/102641, nationalized in AU, BR, CA, CN, EA, EP (EP2800580), IN, JP, KR, MX, NZ, SG, UA, US (US20150023991), HK.
Further Reading
Scientific publications:
1) A vaccine targeting mutant IDH1 induces antitumour immunity.” Published by T. Schuhmacher et al. in Nature. 2014 Aug 21;512(7514):324-7.
2) „Mutant IDH1: An immunotherapeutic target in tumors.“ published by T. Schuhmacher et al. in Onco-immunology. 2015 Jan 7;3 (12):e974392.